A high prevalence of the rtI187V polymerase substitution of hepatitis B virus (HBV) was detected in nucleoside/nucleotide-analogue-naive and -treated chronic hepatitis B (CHB) patients. We aimed at assessing the replicative capacity and susceptibility to lamivudine (LAM) and adefovir (ADV) in vitro of HBV harbouring rtI187V alone or in conjunction with LAM-or ADV-resistant mutations. The reverse transcriptase region of HBV isolates was directly sequenced from a cohort of 300 CHB patients from China. Replication-competent HBV constructs containing rtI187V and combined with LAM-resistant (rtM204I, rtL180M/rtM204V) mutations were generated, and compared with WT, LAM-resistant single (rtM204I) or double (rtL180M/rtM204V) and ADVresistant (rtN236T) clones. In a Chinese cohort of 300 CHB patients, 8.7 % (26/300) showed substitution of rtI187 with V. Of note, the rtI187V prevalence in HBV genotype B was significantly higher than that in HBV genotype C (95.2 vs 4.8 %). In vitro phenotypic assays showed that the viruses bearing the rtI187V substitution had impaired replication efficacy when compared with the WT and the virus carrying rtI187V combined with LAM-resistant single or double mutations showed even more significantly impaired replicative capacities. Furthermore, rtI187V HBV remained susceptible towards treatment with LAM or ADV in vitro whereas the combination of the rtI187V substitution with LAM-resistant mutations rendered HBV resistant to LAM but still sensitive to ADV. Our study revealed that the rtI187V substitution in the HBV polymerase frequently occurred in CHB patients, particularly those with HBV genotype B. However, the emergence of the rtI187V substitution significantly impaired viral replication but without affecting drug sensitivity in vitro.
INTRODUCTION
Hepatitis B virus (HBV) can cause infectious inflammatory illness. According to the most recent World Health Organization (WHO) estimate, approximately two billion people worldwide have been infected with HBV, and among them 240 million have long-term chronic liver infections. China is a highly endemic area; there are an estimated 93 million HBV carriers, and among them 30 million are chronic hepatitis B (CHB) patients (Lu & Zhuang, 2009 ). The current agents for the treatment of CHB in China include immunomodulatory agents, such as IFN-a and pegylated IFN-a, and oral antiviral agents, including lamivudine (LAM), adefovir (ADV), entecavir, telbivudine and tenofovir (TDV) (Lam et al., 2011; Min & Dienstag, 2007; Papatheodoridis et al., 2008) . LAM, the first nucleoside analogue (NA), is still the first-line antiviral drug for treatment of CHB in China. However, the effectiveness of NAs is hampered by the development of mutations in the reverse transcriptase (RT) resulting in progressive liver disease. ADV is also effective against HBV and does not show cross-resistance to lamivudine. It is often used for the treatment of HBV patients resistant to LAM (Lada et al., 2004; Lim et al., 2012) . Although LAM at the dosage used has higher incidence of creating drug resistance (HBV remains sensitive to ADV or TDV), it remains to be a popular antiviral drug in many parts of the world because of its lower cost, excellent safety profile in long-term use and absence of oncogenic potential in animal studies (Yeh et al., 2011) . NAs inhibit HBV replication through their phosphorylated-metabolite action on HBV DNA polymerase (Krishnan et al., 2002) . However, a long duration of NA therapy is associated with an increasing risk of development of drug resistance (Fung et al., 2011) . Liang, 2001; Malik et al., 2012; Suk et al., 2002) . Evolution of mutations that confer a great degree of resistance and restore replication fitness can be associated with progression of liver disease (Yim et al., 2006; Zhong et al., 2012) .
In this study, we analysed nucleotide and amino acid sequences of 300 CHB patients from China. We identified a relatively high prevalence of novel rtI187V substitution in the B domain of the RT found in both NA-naive and NA-treated patients. This caused amino acid substitution rtI187V, with nucleoside position 690 mutated from A to G and no amino acid changed at the corresponding overlapping S gene. We examined the impact of the rtI187V substitution of HBV polymerase on the replication efficacy as well as susceptibility to LAM and ADV in comparison with WT, LAM-and ADV-resistant viruses in vitro.
RESULTS
High prevalence of rtI187V polymerase substitution in a large cohort of CHB patients
We analysed HBV isolates from a cohort of 300 CHB patients from China by direct sequencing of the polymerase region. Based on the comparison of amino acid sequences obtained in this study with corresponding genotype consensus reference sequences (GenBank accession numbers, genotype A: D00329, AF100309 and AB033554; genotype B: X04615, AY123041 and AB014381), we found a relatively high frequency of substitution at position rt187 from isoleucine to valine (rtI187V). In total, 8.7 % (26/300) showed substitutions in the rtI187V locus (22 males/4 females, 14 NA-naive, 4 LAM-treated, 2 ADV-treated, 3 sequential LAM-and ADV-treated, 3 LAM add-on ADVtreated).
Patients with rtI187V polymerase substitution did not display significant differences as compared with patients with WT HBV with respect to age and sex (Table 1) . Moreover, rtI187V substitution showed no significant difference between NA-treated and NA-naive patients (53.8 % vs 46.2 %). Of note, rtI187V was found more frequently in HBV genotype B than HBV genotype C (92.3 % vs 7.7 %).
Influence of rtI187V substitution and drugresistant mutations on intracellular HBV DNA replication efficacy It has been demonstrated that mutations of the HBV polymerase impact susceptibility to NAs as well as viral replication fitness (Fu & Cheng, 1998; Malik et al., 2012; Tacke et al., 2004a) . Here, we aimed to understand the impact of rtI187V substitution on viral replication. Replication-competent HBV constructs harbouring the rtI187V substitution were constructed and compared with WT as well as LAM-(rtM204I, rtM204V/rtL180M) and ADV-resistant (rtN236T) constructs. The intracellular replication efficacies of these constructs were analysed by isolating the HBV replicative intermediates. Briefly, intracellular HBV nucleocapsids were harvested from cell lysates 4 days after transient transfection of HepG2 cells, and intracellular replicative intermediates were isolated and detected by Southern blot. The amount of detected HBV replicative intermediates (Fig. 1a) was normalized to total protein content of cell lysates and b-galactosidase (b-Gal) transfection efficacy. The intensity of the signals was quantified by using Image J software and was normalized to the WT (Fig. 1b) . The rtI187V mutant showed a reduced replication level when compared with the WT. In accordance with a previous study (Fu & Cheng, 1998) , HBV DNA levels were significantly reduced in LAM-resistant mutations (rtM204I or rtM204V/rtL180M). However, combination of these mutations with rtI187V resulted in further reduced HBV intracellular DNA levels, especially in the rtL180M/rtM204V/rtI187V combined mutation, which could not be detected by Southern blot. Furthermore, the rtI187V substitution did not affect the secretion of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the supernatant (Fig. 2a) . However, these data showed that the rtI187V substitution affected viral replication efficiency, especially when combined with LAM-resistant mutations.
RtI187V substitution did not confer resistance to LAM and ADV
To test the susceptibility of HBV harbouring the rtI187V substitution to the antiviral drug LAM, cells were transiently transfected as described in Methods and kept in the presence of increasing concentrations of LAM or ADV for 4 days by quantifying HBV replicative intermediates using Southern blot analysis (Fig. 3a) . Due to the markedly decreased replication efficacies conferred by the combination mutations (rtM204I/rtI187V, rtM204V/rtL180M/ rtI187V), intracellular viral replication almost cannot be detected by Southern blot, so secreted HBV virions from supernatant were PEG-precipitated and measured by real-time PCR (Fig. 3c) . As shown in Fig. 3(b, c) , LAM significantly reduced the viral replication and HBV viral load of WT HBV and that carrying the rtI187V substitution. Whereas, the rtL180M/rtM204V construct conferred resistance to LAM. By contrast, introduction of the rtI187V substitution into a LAM-resistant (rtL180M/ rtM204V) background did not affect the drug sensitivity of LAM-resistant mutations to LAM as quantified by HBV extracellular virions (Fig. 3c) .
Susceptibility of rt187 substitution and drugresistant mutants to ADV in vitro
To test the susceptibility of the different HBV mutants to the antiviral drug ADV, cells were treated as described in detecting susceptibility to LAM. As shown in Fig. 4 , all constructs except rtN236T were sensitive to ADV. 
DISCUSSION
Available antiviral agents are effective in suppressing HBV replication with the advantage of delaying disease progression (Chae & Hann, 2007; Tillmann, 2007) . However, high genetic variability confers a biological advantage, allowing HBV the ability to escape from the host's antiviral immune responses and develop drug resistance (Melegari et al., 1998) . Naturally occurring mutations of RT in treatmentnaive patients have been reported in asymptomatic HBV carriers or CHB patients (Zheng et al., 2012) . However, the impact of naturally occurring mutations in treatmentnaive patients with CHB has not been fully evaluated. In this study, we report the prevalence and molecular and functional consequences of HBV variants harbouring the rtI187V substitution in 300 CHB patients. To our knowledge, this is the first time the impact of the rtI187V polymerase substitution on HBV replication efficiency has been addressed.
The rtI187V substitution was frequently detected in LAM-resistant patients. However, the relationship between rtI187V and LAM resistance has not been investigated. It is possible that the relatively high incidence of rtI187V substitutions in our cohort may be related to particularities of the patient population; all patients were recruited from southern China and 76.7 % (230/300) of the patients were infected by HBV genotype B. This is consistent with other studies that genotype B is most commonly found in southern China (Zhang et al., 2011) . Moreover, the rtI187V substitution is found significantly more frequently in genotype B than in genotype C, which could be interpreted as certain patterns are restricted by functional constraints on a particular genotype (Warner et al., 2007) . The genotype of HBV (B vs C) may play an important role in the prevalence of this substitution. Furthermore, our cell culture study also demonstrated that HBV isolates carrying the rtL180M/rtM204V mutation replicated better than those harbouring rtL180M/rtM204V/rtI187V. This suggested the possibility of better progression of LAM treatment in patients with the rtI187V substitution. A larger patient population study will be worthwhile in addressing the issue. In this study, we also aimed to identify the impact of a high prevalence substitution, rtI187V, within the HBV polymerase region on viral replication capacity as well as antiviral drug susceptibility using HBV constructs. In vitro phenotypic studies showed that rtI187V, LAM-(rtM204I, rtM204V/rtL180M) and ADV-resistant (rtN236T) mutations conferred significantly impaired viral replication efficiencies while rtL180M conferred an equivalent replication capacity when compared with the WT, confirming previous results of other investigators (Amini-Bavil-Olyaee et al., 2009b; Brunelle et al., 2005; Fu & Cheng, 1998; Lada et al., 2004; Tacke et al., 2004b) . However, the rtI187V substitution showed a stronger effect in decreasing the intracellular DNA replication efficiency conferred by LAMresistant mutations. Drug sensitivity assays showed that rtI187V mutants remain susceptible to LAM as well as ADV, similar to the WT. Furthermore, isolates containing the rtI187V substitution together with LAM-resistant constructs (rtM204I, rtM204V/rtL180M) showed similar sensitivity to LAM and ADV as those harbouring LAMresistant constructs. Our results demonstrated that the rtI187V mutation impairs viral replication efficiency without affecting susceptibility to LAM or ADV in vitro.
This study also found that, regardless of the selective pressure of drug, the replication of intracellular HBV DNA decreased significantly with either rtM204I/rtI187V or rtM204V/rtL180M/rtI187V. Therefore, it was easy to clear intracellular DNA during antiviral treatment in CHB patients with this kind of mutation.
Taken together, the presence of the rtI187V substitution confers the same sensitivity to LAM and ADV as the WT. Mutations related to LAM resistance could affect both genotype and susceptibility to LAM but have no impact on susceptibility to ADV. These observations may have important clinical implications; rtI187V HBV of patients treated by LAM or ADV may have less incidence or delayed onset of developing LAM resistance unless new compensatory mutants of RT occur, which was not been observed yet. If this is correct, surveillance of the rtI187V substitution of HBV may be useful for progression of LAM treatment. A large cohort study should be initiated to test this hypothesis.
METHODS
Patient cohort. Serum samples were obtained from a large cohort of 300 CHB patients from China that were recruited between 2008 and 2009. They were 85 % males and 15 % females with a median age of 33 years (range 9-70 years). The patients were grouped into five groups including NA-naive group (n5169), LAM-treated group (n560), ADV-treated-group (n537), sequential LAM and ADV-treated group (n516) and LAM add-on ADV-treated group (treated with LAM and ADV due to the emergence of LAM resistance) (n518). No other NAs were administered. Exclusion criteria included hepatitis C, hepatitis D and human immunodeficiency virus co-infection. HBV DNA was extracted from serum samples and sequenced. Phylogenetic analysis revealed that 76.7 % patients were infected by genotype B HBV and 23.3 % were infected by genotype C HBV. All of the protocols for the collection and handling of patient samples and data were reviewed and approved by the ethics committee of the Shanghai Jiao Tong University School of Medicine, in compliance with the Helsinki Declaration of the World Medical Association. All samples were collected for routine clinical detection, with doctor's prescription and patients' informed consent.
Generation of HBV polymerase mutants. The plasmid pHBV-adr encodes a WT, terminally redundant (1.1-genome-length), replication-competent HBV genome, which was a gift from Yuan Wang, Shanghai Institute of Biochemistry, Chinese Academy of Sciences (Fu & Cheng, 2000; Fu et al., 1996) . It was used as a WT control and as a template in the site-directed mutagenesis performed with a Quick Change II site-directed mutagenesis kit (Stratagene). After generation of constructs, all were confirmed by digestion followed by sequencing the HBV RT region.
Cell culture and transfection. Human hepatoblastoma HepG2 cells (from the American Type Culture Collection) were cultured in minimum essential medium (MEM, Gibco) supplemented with 10 % FBS and 100 U kanamycin ml
21
. HepG2 cells were incubated in a humidified incubator at 37 uC with 5 % CO 2 . Six-well plates were seeded with 7610 5 HepG2 cells per well a day earlier and transiently transfected by the replication-competent HBV plasmids (3 mg per well of six-well plate) using Lipofectamine 2000 following the manufacturer's protocol (Invitrogen). The transfected cells were harvested after 4 days. pSV-b-Gal control vector (0.3 mg; Promega) was co-transfected to assess transfection efficiency and measurement of b-Gal activity from cell lysates as described by Bock et al. (2002) . All experiments were performed three times.
Isolation of HBV intracellular replicative intermediates. HBV intracellular replicative intermediates were isolated from transfected cells as described by Zhong et al. (2012) . Briefly, cells were harvested 4 days after transfection and lysed with a buffer containing 1 % NP-40. Total protein content of the cell lysates was quantified using a BioRad protein assay according to the instructions of the manufacturer. Cell lysates were centrifuged for 5 min at 10 000 g. Supernatants were treated with DNase I (100 mg ml 21 ) and RNase A (100 mg ml 21 ) (Roche) with 10 mM MgCl 2 , and incubated at 37 uC for 1.5 h to eliminate contaminating plasmid HBV DNA. After that, HBV capsids were digested by using 25 mM EDTA/100 mM NaCl/1 % SDS (w/v)/ 200 mg proteinase K ml
, and incubated at 50 uC for 2 h, followed by phenol/chloroform extraction and precipitation with 2-propanol. Pellets containing viral DNA were dissolved in double distilled water before analysis by Southern blot.
Analysis of HBV intracellular replicative intermediates by
Southern blot hybridization and quantification. The intracellular HBV DNA replicative intermediate was detected by a full-length HBV DNA probe labelled with digoxigenin-dUTP (Roche). The signal intensity data were quantified using Image J software (Bio-Rad) and normalized to total protein content of the cell lysates and transfection efficiency. HBV viral particles were precipitated from the cell culture supernatant 4 days after transfection using polyethylene glycol 8000 (10 %, v/v) in 1.5 M NaCl at 4 uC overnight followed by DNase I and RNase A digestion (Roche). HBV DNA was extracted by proteinase K/SDS, phenol/chloroform extraction, and 2-propanol precipitation of mature HBV DNA, as described above. To determine HBV viral load in cell culture supernatant, a real-time PCR was carried out on a 157 bp fragment from a highly conserved region of the HBV-S gene amplified using SsoFast EvaGreen Supermix (Bio-Rad) (AminiBavil-Olyaee et al., 2009a) . A standard curve was prepared using 10-fold serial dilutions of the HBV WT vector, and viral load was quantified by the Bio-Rad CFX connect real-time PCR machine. After quantification of HBV DNA copy numbers, the viral load was normalized to b-Gal transfection efficiency.
Detection of HBV protein in supernatant. HBsAg and HBeAg in culture medium were quantified by ELISA (Abnova).
Antiviral compounds and drug susceptibility assays. LAM was provided by Chung K. Chu from the University of Georgia. ADV was kindly provided by Gilead Sciences. Stock solutions for LAM (100 mM) and ADV (16.8 mM) were dissolved in sterile distilled water, aliquoted and stored frozen at 220 uC. The analyses of drug susceptibility were performed after transient transfection of HepG2 cells with recombinant WT and mutant clones. After 1 day, the medium containing various concentrations of each antiviral drug was changed every day and cells were harvested after 4 days. The concentration of LAM used was 0, 0.01, 0.1, 1, 3 and 10 mM for WT HBV, and 0, 0.01, 0.1, 1, 10 and 100 mM for HBV containing LAMresistant mutations; the concentration of ADV used was 0, 0.01, 0.1, 1, 10 and 25 mM. The transfection efficiency was assessed by cotransfection of a plasmid encoding b-Gal performed and b-Gal enzyme assay (Promega). Southern blot results were normalized to the total protein content of the cell lysates and transfection efficiency based on b-Gal activity.
Statistical analysis. Data are reported as means±SD. Groups' comparisons were performed using Student's t-test. All statistical analyses were carried out with SPSS software. A P value of less than 0.05 was considered statistically significant.
